Lyman BioPharma Consulting LLC

Advice and Resources for the Biotech Industry

Advice and Resources for the Biotech Industry

Stacks Image 512

Blue vintage pill bottles shelf

Is Pharma Really Facing Its Demise?

A widely reported
op-ed piece recently predicted the upcoming financial demise of the pharmaceutical industry. Some have opined, “there’s nowhere to go but down.” While it’s true that the industry faces strong headwinds (many of its own making), I don’t think it’s going to fold anytime soon. Reports of its upcoming demise are, as the saying goes, greatly exaggerated. There’s been an uptick in drug approvals in 2017 (the highest in over a decade), and some of the newest drugs cost upwards of half a million dollars or more. Global sales of biopharma medicines jumped 45 percent from 2006 to 2015. Cancer drug sales in particular are soaring. New biomedical innovations, such as CAR-T immunotherapies and gene modifications using the CRISPR-Cas9 system, appear promising to help treat mankind’s ills.

Let’s take the long view: how has the industry expanded and flourished over the past century? I was recently reading the centennial issue of Forbes, which listed the top 50 U.S. companies (ranked by market cap) from 1917, 1967 (the magazine’s 50
th anniversary), and 2017 (100th anniversary). Comparing these time points provides a fine illustration of just how financially successful the pharmaceutical industry has become over the past one hundred years.

Brick wall (550)

What to Read To Get the Latest BioPharma/Healthcare Info

One question I’m frequently asked: what do you read to keep up with developments in biopharma? My recommendations are below, but keep in mind that my needs may be different from yours. It depends on an individuals background, their interests, how they plan to use that information, and how much they want to spend. Most people will give disparate answers to this question, and that’s just how it should be.

non compete 550

Illustration: Josh Lyman

Non-Compete Agreements: Dangerous Liaisons

I was recently contacted by outside counsel for a large biopharma company about doing some consulting work for them. We discussed the general scope of the project by phone, and quickly reached agreement that I would be able to help them with their task. The next step was to sign a consulting agreement, which was par for the course. When I was emailed the form I was pleasantly surprised to see that the agreement was only one and half pages long. Many of the consulting contracts I’ve signed for other organizations are typically eight to ten pages. They force me to carefully step through a minefield of minutiae to ensure that the agreement is fairly written for both parties. This one, I thought, would be easy to review and sign.

Then I read it…


Sci-hub vs ipubsci 550

Sci-Hub vs. iPubSci: Another Look at Accessing Unaffordable Science Journals

Anyone who’s ever tried to access the scientific literature knows that science journals are incredibly expensive. Subscriptions often cost hundreds, if not thousands of dollars per journal title. Purchasing individual papers online (often at $30 to $35 apiece) is equally problematic; I’ve
estimated that about three quarters of articles in the scientific literature are secured behind paywalls. Ironically, one of the articles I wrote about the problem of unaffordable science journals is now sequestered behind the Nature Biotechnology paywall (it was originally freely available). The high cost of journals hinders access by both lay people as well as physicians and many scientists (mostly those outside of academia). The unaffordability of science journals serves as an impediment to the success of small biotechnology companies. It makes it difficult for the scientists who work there to keep current with the latest developments in their fields. It’s hard to be competitive as an R&D organization when you can’t afford access to the key papers that may steer your research one way or another. Equally troubling is the other side of the coin: rising costs (to the authors) for publishing papers. These can now exceed $5,000 for some open access journals (in which those who submit the articles pay a fee, rather than the end users), and costs have been rising at a pace much higher than the overall inflation rate.

Health insurance question 550

Health Insurance Improves Patients Lives

When I was diagnosed with cancer last year, I was glad that I had good health insurance coverage. I hadn’t realized it at the time, but I now know that I really had nothing to worry about. It turns out that having insurance is not really all that important for our health and well-being. I know this because Congressman Raul Labrador (R-Idaho) told us so. As he
put it, “Nobody dies because they don’t have access to health care.” That might be true on some planet, but not on this one. Politifact, which identified a number of studies that showed having health insurance indeed prevents people from dying, later rated this ridiculous claim as “Pants on Fire.”

Charlie M's band 550

Rock Lyrics Predicted Drug Discoveries

Many people know that an eternal link exists between science and music. For example, Russian composer Alexander Borodin was as well known for his
chemical work on aldehydes as his symphonies and string quartets. Many scientists have side careers, or at least hobbies, as musicians. These include NIH Director Francis Collins, who has entertained many people with his singing and guitar playing (note the inlaid mother-of-pearl double helix on the guitar’s fretboard).


What you may have missed is that many rock musicians, who’ve long been associated with illicit drug abuse, clearly envisioned numerous modern pharmaceutical innovations in their songs. I’m not talking about overt drug tracks like J.J. Cale’s Cocaine (popularized by Eric Clapton), the Beatles Doctor Robert, or the Rolling Stones’ Mother’s Little Helper. I’m talkin’ tunes that predated and anticipated later medicinal developments, as reflected in their lyrics. Let me share a few examples.